Abstract: The present invention relates to methods for prevention and treatment of bone-related or nutrition-related disorders using a GLP molecule or GLP activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.

Abstract: The disclosure concerns stable expression systems for production of a protein comprising: a) a species of Acanthamoeba as a host organism; b) a DNA vector which comprises a selection marker gene which codes for a protein which, after transformation of the host organism, allows selection of positive transformants, where expression of the selection marker gene is controlled by at least one genetic regulatory element which is homologous in the host organism; and c) a DNA vector which comprises a heterologous gene for the expression of a heterologous protein, where the expression of the protein is controlled by at least one genetic regulatory element which is homologous to the host organism.

Abstract: The present invention provides methods of determining aggregation of &agr;-synuclein, which are a hallmark of Lewy body diseases such as Parkinson's disease. Also disclosed are inhibitors of the aggregation, including magnesium and &agr;-synuclein binding peptides. The inhibitors are useful in the treatment of Lewy body diseases.

Abstract: A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17&bgr;-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17&bgr;-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 &mgr;g per day of norgestimate.

Abstract: The present invention relates to compounds of formula (IA): the preparation thereof, pharmaceutical formulations thereof, and their use in medicine as allosteric adenosine receptor modulators for uses including protection against hypoxia and ischemia induced injury and treatment of adenosine-sensitive cardiac arrhythmias.

Abstract: The present invention relates to the therapeutic use of non-amine tropane analogues that bind to the SERT to treat neuropsychiatric disorders.

Abstract: New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7-substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.

Abstract: The present invention relates to a secondary battery case being molded by a thermoplastic resin composition comprising: (A) a polyphenylene ether-based resin, (B) a crystalline polypropylene resin which is a homopolymer or a copolymer of polypropylene, and (C) a hydrogenated block copolymer comprising an aromatic vinyl compound polymer block and a conjugated diene compound polymer block, the (A)/(B) ratio by weight being 7/93 to 70/30, the amount of (C) being 2 to 40 parts by weight based on 100 parts by weight of (A) and (B) combined, the melt flow rate of said crystalline polypropylene resin (B) being 0.1 to 10 g/10 min as measured according to JIS K-7210 at 230° C. and 21.17 N, the density of the propylene polymer moiety in said crystalline polypropylene resin being not less than 0.906 g/cm3.

Abstract: A photocatalyst article exhibits high photocatalytic activity even in environments illuminated by weak ultraviolet light or visible light, expresses excellent anti-fogging and anti-soiling properties, and retains good anti-fogging and anti-soiling performance over long periods and therefore has a high utilization value as an anti-fogging, anti-soiling article. The photocatalyst article contains an oxide semiconductor and a compound which contains at least one type of element selected from the group comprised of Mg, Sc, V, Cr, Mn, Y, Nb, Mo, Ru, W, and Re, at a content such that the ratio (A/B) of the number of metal atoms of the abovementioned element (A) to the number of atoms of metal that comprise the abovementioned oxide semiconductor (B) will be about 0.20 to 2.